Parkinson's disease (PD) is the most common movement disorder affecting more than 4
million people worldwide. The primary motor symptoms of the disease are due to …

The worldwide prevalence of movement disorders is increasing day by day. Parkinson's
disease (PD) is the most common movement disorder. In general, the clinical manifestations …

With increased histone deacetylase (HDAC) activity and histone hypoacetylation being
implicated in neurodegeneration, HDAC inhibitors have been reported to have considerable …

Understanding the contribution of imbalance in protein acetylation levels and dysfunction of
transcription to neurodegenerative diseases provides the rationale for the use of epigenetic …

During the past six years numerous studies identified histone deacetylase (HDAC) inhibitors
as candidate drugs for the treatment of neurodegenerative disorders. Two major …

BACKGROUND AND PURPOSE Prevention or disease‐modifying therapies are critical for
the treatment of neurodegenerative disorders such as Alzheimer's disease, Parkinson's …

Background & Objective: Imbalance in histone acetylation levels and consequently the
dysfunction in transcription are associated with a wide variety of neurodegenerative …

Histone hypoacetylation is associated with dopaminergic neurodegeneration in Parkinson's
disease (PD), because of an imbalance in the activities of the enzymes responsible for …

Despite the applicability of histone deacetylase inhibitors (HDACis) for cancer treatment,
several works in the literature have shown that these inhibitors can be used in several other …

The use of histone deacetylase inhibitors (HDACIs) as a therapeutic tool for
neurodegenerative disorders has been examined with great interest in the last decade. The …